Breast cancer experts address frequently asked questions on adjuvant and metastatic CDK4/6 inhibitor selection in HR-positive breast cancer.
|Articles|August 13, 2021
The Evolving Role of PI3K Inhibitors in the Treatment of Follicular Lymphoma
On June 18, 2021, OncLive® brought together a group of oncologists who specialize in the treatment of follicular lymphoma to participate in a virtual workshop to discuss the evolving role of PI3K inhibitors in the treatment of follicular lymphoma. This article summarizes key data about PI3K inhibitors as a therapeutic target as well as insights from stakeholder discussions regarding this topic.
Advertisement
Advertisement
Related to this article
The European Commission approved pembrolizumab plus enfortumab vedotin for muscle-invasive bladder cancer, irrespective of cisplatin eligibility.
Thoracic oncologists weigh how TROP2-directed antibody-drug conjugates fit into sequencing and combination strategies for EGFR-mutated NSCLC.
Patients with pancreatic cancer experience measurable changes in body composition years before diagnosis that differ from those seen in similar individuals without cancer.
Lisaftoclax plus acalabrutinib earned breakthrough therapy status in China for untreated CLL/SLL.
Andrea Cercek, MD, discusses the FDA approval of dostarlimab and its significance for dMMR locally advanced rectal cancer management.
Fadi Haddad, MD, discusses TKI adherence barriers, adverse effect management, and the role of alternative TKI formulations in CML.
Updated ARC-20 data showed casdatifan activity as monotherapy and in combinations across treatment lines in advanced clear cell RCC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval of Dostarlimab Brings Potential Organ-Sparing Approach in dMMR Locally Advanced Rectal Cancer
2
Treatment Tailoring and Weighing Alternative Formulations Support Optimal TKI Deployment in CML
3
HER2+ Maintenance Therapy Approvals and Innovative Brain Metastasis Care Reshape Breast Cancer Management
4
Lisaftoclax Plus Acalabrutinib Received Breakthrough Therapy Designation in China for Treatment-Naive CLL/SLL
5